Results 51 to 60 of about 50,558 (217)
, 2023 Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zheng Y +8 more
core
Journal of International Medical ResearchNirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong +4 more
doaj +1 more source
Clinical Pharmacology: Advances and Applications, 2021 Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Vermunt M, Marchetti S, Beijnen J
doaj
The effect of ritonavir on the pharmacokinetics of clonidine
Pakistan Journal of Pharmaceutical Sciences, 2023 This project aims to explore the repercussions of ritonavir on both the drug kinetics of clonidine in rats and clonidine metabolism in liver microsomes.
in vivo +4 more
doaj +1 more source
The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis
Epileptic Disorders, EarlyView.Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino +5 more
wiley +1 more source
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study [PDF]
Scripta Medica, 2019 Background: The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection.
Verhaz Antonija +3 more
doaj
EClinicalMedicine, 2023 Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García +115 more
doaj +1 more source
A real‐world analysis of AI chatbot performance for medicines information enquiries
Journal of Pharmacy Practice and Research, EarlyView.Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston +2 more
wiley +1 more source
Nirmatrelvir Plus Ritonavir: First Approval
, 2022 DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Yvette Lamb (6930427)
core +1 more source
Pharmaceuticals, 2014 Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors.
Ramesh B. Batchu +10 more
doaj +1 more source